Department of Psychiatry, Columbia University, New York, United States; Department of Molecular Therapeutics, NYS Psychiatric Institute, New York, United States
Nao Chuhma
Department of Psychiatry, Columbia University, New York, United States; Department of Molecular Therapeutics, NYS Psychiatric Institute, New York, United States
Abigail Kalmbach
Department of Psychiatry, Columbia University, New York, United States; Department of Molecular Therapeutics, NYS Psychiatric Institute, New York, United States
Gretchen M Thomsen
Department of Psychiatry, Columbia University, New York, United States
Yvonne Wang
Department of Psychiatry, Columbia University, New York, United States
Andra Mihali
Department of Psychiatry, Columbia University, New York, United States
Department of Psychiatry, Columbia University, New York, United States
Ilana Zucker-Scharff
Department of Psychiatry, Columbia University, New York, United States
Anna-Claire Siena
Department of Molecular Therapeutics, NYS Psychiatric Institute, New York, United States
Martha G Welch
Department of Psychiatry, Columbia University, New York, United States; Department of Pediatrics, Columbia University, New York, United States; Department of Developmental Neuroscience, NYS Psychiatric Institute, New York, United States
José Lizardi-Ortiz
Department of Neurology, Columbia University, New York, United States
Department of Psychiatry, Columbia University, New York, United States; Department of Molecular Therapeutics, NYS Psychiatric Institute, New York, United States; Department of Neurology, Columbia University, New York, United States; Department of Pharmacology, Columbia University, New York, United States
Holly Moore
Department of Psychiatry, Columbia University, New York, United States; Department of Integrative Neuroscience, NYS Psychiatric Institute, New York, United States
Inna Gaisler-Salomon
Department of Psychiatry, Columbia University, New York, United States; Department of Psychology, University of Haifa, Haifa, Israel
Department of Psychiatry, Columbia University, New York, United States; Department of Molecular Therapeutics, NYS Psychiatric Institute, New York, United States
Dopamine neurons in the ventral tegmental area use glutamate as a cotransmitter. To elucidate the behavioral role of the cotransmission, we targeted the glutamate-recycling enzyme glutaminase (gene Gls1). In mice with a dopamine transporter (Slc6a3)-driven conditional heterozygous (cHET) reduction of Gls1 in their dopamine neurons, dopamine neuron survival and transmission were unaffected, while glutamate cotransmission at phasic firing frequencies was reduced, enabling a selective focus on the cotransmission. The mice showed normal emotional and motor behaviors, and an unaffected response to acute amphetamine. Strikingly, amphetamine sensitization was reduced and latent inhibition potentiated. These behavioral effects, also seen in global GLS1 HETs with a schizophrenia resilience phenotype, were not seen in mice with an Emx1-driven forebrain reduction affecting most brain glutamatergic neurons. Thus, a reduction in dopamine neuron glutamate cotransmission appears to mediate significant components of the GLS1 HET schizophrenia resilience phenotype, and glutamate cotransmission appears to be important in attribution of motivational salience.